StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$18.60+0.25 (+1.36%)

Close on Nov 13, 2026Market cap $102.18MP/E –Yield –

Earnings

InMed Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of InMed Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Sep 30, 2026Nov 10, 2026after the close–––Release
Q1 FY2021ended Sep 30, 2020Nov 13, 2020during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

InMed Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When InMed Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases InMed Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. News
  5. Update
  6. News
  7. Update
  8. Update
  9. News
  10. Update
  11. Update
  12. Update
  13. News
  14. Update
  15. News

See a number that looks wrong?